PT  - JOURNAL ARTICLE
AU  - Vinall, Maria
ED  - Bielack, Stefan S.
TI  - Results from the EURAMOS-1 Trial
DP  - 2013 Aug 01
TA  - MD Conference Express
PG  - 25--25
VI  - 13
IP  - 6
4099  - http://mdc.sagepub.com/content/13/6/25.short
4100  - http://mdc.sagepub.com/content/13/6/25.full
AB  - Results from the Combination Therapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma trial [EURAMOS-1; NCT00134030; J Clin Oncol 2013 (suppl; abstr LBA10504)] show that maintenance therapy with pegylated interferon a-2b (PEG IFN-a-2b) after surgery and chemotherapy does not improve event-free survival in patients with high-grade osteosarcoma and good response to preoperative methotrexate, doxorubicin, and cisplatin (regimen collectively called MAP).